The Impact of Antimicrobial Therapy in IPF
Weill Cornell Medicine
Clean-UP IPF was the first pragmatic trial in IPF that studied whether antimicrobial therapy would improve hospitalization or decrease death. Pragmatic trials are aimed at evaluating the effectiveness of treatments in real-life settings.
The study was a collaboration with the National Heart, Lung, and Blood Institute (NHLBI), several philanthropic organizations, and a broad investigative community. While the initiation of the study was delayed, it was fully enrolled several months ahead of time with aggressive recruiting. The study was completed on October 31, 2020.
The lead investigator was Fernando Martinez, MD Chief of the Division of Pulmonary and Critical Care Medicine and Bruce Webster, MD Professor of Medicine at the Weill Cornell Medicine, New York-Presbyterian Hospital.
The study was recently published in the May 2021 issue of the Journal of the American Medical Association (JAMA). The PDF for the article, “Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: The CleanUP-IPF Randomized Clinical Trial” was published in the Journal of the American Medical Association (JAMA). A PDF can be found in the Publications section of this site or by clicking here.
Three Lakes Foundation has provided funding to support Enlil Therapeutics in its quest to identify compounds that activate telomerase.
B4PF: Understanding Early Disease
To develop therapies that prevent the development of PF, it is essential to study the earliest aspects of disease pathogenesis.
A Global Collaboration for PF
Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is a clinically focused research program funded by the Australian National Health and Medical Research Council.